Compare International Flavors & Fragrances Inc. Common Stock (IFF) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
International Flavors & Fragrances Inc. Common Stock vs Tango Therapeutics Inc. — how do they compare? International Flavors & Fragrances Inc. Common Stock trades at $89.51 (market cap $22.50B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: International Flavors & Fragrances Inc. Common Stock is far larger — about 6× Tango Therapeutics Inc.'s market cap, and International Flavors & Fragrances Inc. Common Stock pays a 1.81% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold International Flavors & Fragrances Inc. Common Stock for 6 Days and Tango Therapeutics Inc. for 0 Days on average.
| IFF | TNGX | |
|---|---|---|
Market Cap | $22.50B | $3.75B |
Volume | 3,000,517 | 9,619,106 |
Sector | Basic Materials | Health |
52-Week High | $89.60 | $32.90 |
52-Week Low | $61.49 | $7.50 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $28.18B | $2.77B |
Dividend Yield | 1.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IFF trades at $88.2, up 3.81% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported a net loss of $361 million in 2025 but returned to profitability in 2026 with $277 million net income. Recent news highlights product innovations like AQUASCENT™ and life-stage dairy insights. Analyst consensus is strongly bullish with a $95 price target, though valuation ratios like P/E of 80.92 appear elevated relative to earnings.
The outlook for IFF hinges on sustaining its 2026 profitability turnaround and executing growth initiatives. Investment opportunities include market leadership in flavors and fragrances and new technology launches. Key risks are high debt levels, competitive pressures, and sensitivity to consumer spending trends. The stock's upside is supported by analyst optimism but requires careful monitoring of earnings consistency.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About International Flavors & Fragrances Inc. Common Stock
International Flavors & Fragrances develops ingredients and solutions used in food, beverages, personal care, home care, health, and biosciences applications. Its portfolio includes flavors, fragrances, cultures, enzymes, and nutrition ingredients.
Read more on IFF →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
